LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
PARSIPPANY, N.J., Nov. 10, 2016 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that senior leadership is scheduled to present an overview of the company at the following investor conferences in November:
- Jefferies 2016 London Healthcare Conference at 2:00 p.m. GMT (7:00 p.m. ET) in London on Thursday, November 17, 2016.
- 28th Annual Piper Jaffray Healthcare Conference at 11:00 a.m. ET in New York on Tuesday, November 29, 2016.
Live audio webcasts of the Pacira presentations can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. Replays of the webcasts will be archived on the Pacira website for two weeks following the respective presentation dates.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Jessica Cho, (973) 254-3574 [email protected]
